You just read:

Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence

News provided by

Daiichi Sankyo Company, Limited

01 Sep, 2013, 07:15 BST